Metastasis of cancer cells to distant organ systems is a complex process that is initiated with 3 the programming of cells in the primary tumor. The formation of distant metastatic foci is correlated 4 with poor prognosis and limited effective treatment options. We and others have correlated Mouse 5 double minute 2 (Mdm2) with metastasis; however, the mechanisms involved have not been 6 elucidated. Here it is reported that shRNA-mediated silencing of Mdm2 inhibits epithelial-7 mesenchymal transition (EMT) and cell migration. In vivo analysis demonstrates that silencing Mdm2 8 in both post-EMT and basal/ triple negative breast cancers resulted in decreased primary tumor 9 vasculature, circulating tumor cells, and metastatic lung foci. Combined, these results demonstrate 10
Introduction 17 18
Metastatic foci arise after primary tumor cells successfully transition through various phases of 19 the metastatic process. These phases include invasive migration from the primary tumor, 20 intravasation into the blood stream, extravasation into a distant organ, and colonization in conducive 21 tissues. In response to avascular hypoxic conditions, primary tumor cells may produce vascular 22 endothelial growth factor (VEGF), which stimulates angiogenesis, recruits endothelial cells for 23 neovascularization, and/or permeabilizes existing vasculature through which tumor cells can 24 intravasate. The dissemination of tumor cells to distant organs can be initiated through an 25
Orthotopic implantation in mice and assessment 12
All animal studies have been approved by Indiana University School of Medicine IACUC 13 (protocol #11190) and were performed by the Indiana University In Vivo Therapeutics Core. 7.5x10 5 
14
TMD 231 shGFP, or shMdm2 cells or 1x10 6 MDA468 shControl or shMdm2 cells were injected into 15 the fourth mammary fat pad of NOD-SCID Gamma mice (n=7 per group) obtained from the In Vivo 16
Therapeutics Core of the Indiana University Simon Cancer Center. Tumor growth was calculated by 17 volumetric analysis using calipers. Tumors were allowed to grow to an average volume of 600 mm 
Circulating tumor cell analysis 22
Cardiac punctures with 1ml TB syringe and a 27G x ½ needle (BD Biosciences) were 23 performed at necropsy and temporarily stored in vacutainers coated with sodium heparin (BD 24 Biosciences) prior to peripheral blood mononuclear cells (PBMC) processing. PBMCs were isolated 1 by Ficoll-paque TM Plus (GE Healthcare) separation and cells were stained with 1 g phycoerythrin 2 (PE) conjugated mouse anti-human EGF Receptor antibody (#555997; BD Pharmigen) per 1x 10 6 3 cells. FACS analysis was conducted and data analysis was performed using FlowJo 10.0.8r1. The 4 percentage of CTC population of each shControl and shMdm2 sample was determined by positive 5 human-specific EGFR staining of CTCs in mouse blood. 6 7
Tissue Processing and Immunostaining 8
Tissues were fixed overnight at room temperature in 10% neutral buffered formalin after which 9 they were transferred through graded concentrations of alcohol to xylene inside a Leica Automated 10
Vacuum Tissue Processor. Samples were embedded in paraffin before being cut into five micron 11 thick sections, mounted onto positively charged slides, and baked at 60 °C. 12
The Indiana University Pathology Core performed all tumor preparation, hematoxylin & eosin 13
(H&E) and CD31 staining, and quantitation. Slides were then deparaffinized in xylene and rehydrated 14 through graded alcohols to water. Antigen retrieval was performed by immersing the slides in Target  15 Retrieval Solution (DAKO) for 20 min at 90 °C, cooling at room temperature for 10 min., washing in 16 water and then proceeding with immunostaining. Slides were blocked with protein blocking solution 17 (Dako) for 30 minutes. All subsequent staining steps were performed using the Dako FLEX SYSTEM 18 on an automated Immunostainer; incubations were done at room temperature and Tris buffered 19 saline plus 0.05% Tween 20, pH 7.4 (TBS -Dako Corp.) was used for all washes and diluents. 20
Thorough washing was performed after each incubation. Standard H&E staining was then performed. 21
Alternatively, slides were stained with anti-mouse CD31 (DIA 310; Dianova). Control sections were 22 treated with an isotype control using the same concentration as primary antibodies to verify the 23 staining specificity. 24 25 8 1
Image Capturing 2
Aperio's whole slide digital imaging system, ScanScope CS, was used for imaging (360 Park 3
Center Drive Vista, CA 92081). All slides were imaged at 20x. Digital images were obtained using 4
Aperio's software, ImageScope. For CD31 analysis, whole primary tumor cross sections were 5 analyzed, with the exception of the excluded necrotic tissue. Vessels less than 125 m and/or having 6 a diameter less than 30 m were considered immature. Data from 5 independent hand counts per 7 tumor were confirmed by a pathologist, averaged and presented as the average percent of immature 8 vessels (the average number of immature vessels divided by the average total vessels in each 9 primary tumor). 10
Lung Metastases Quantification 11
H&E evaluation of lung metastases was performed by a Pathologic Assistant. All hand counts 12 The entire lung of each mouse was scored for metastases and divided by the area of each lung. 16 17 18
Results: 19

The EMT program is regulated by Mdm2 20
To confirm that Mdm2 is required for metastasis, MDA468 and TMD231 cells were transduced 21 with control and Mdm2-specific shRNA lentiviruses. MDA468 cells, a basal-like cell line, can 22 undergo EMT while TMD231 cells, a derivative of MDA231 cells, are post-EMT and resemble 23 mesenchymal cells. Once the cell lines were confirmed for decreased levels of Mdm2 ( Fig. 1a and 24 Fig.S1 ), we analyzed levels of mutp53 since Mdm2 can regulate p53 and many studies have 25 demonstrated that mutp53 promotes tumorigenesis and metastasis (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) . Interestingly, knock-1 down of Mdm2 in the MDA468 cells resulted in an increase in mutp53 levels, while no discernable 2 difference was observed when TMD231 shMdm2 and shControl cells were compared (Fig. 1a) . We 3 next explored whether shMdm2 cell lines would undergo EMT. The mesenchymal marker, SNAI1, 4 was decreased in both shMdm2 cell lines (Fig. 1b) . EMT markers in shControl and shMdm2 MDA468 5 cells were further examined and shMdm2 cells were found to molecularly resemble epithelial cells 6 with regards to E-Cadherin, N-Cadherin, and vimentin ( Fig. 1c and Fig.S1 ). Silencing Mdm2 also 7 resulted in a more epithelial-like morphology compared to the shControl cells (Fig, 1d) , which is 8 consistent with the low level of EMT markers. MDA468 cells were treated with TGFβ1 and hypoxia to 9 induce EMT. While TGFβ1 treatment of shControl cells resulted in increased levels of various 10 mesenchymal markers and a more mesenchymal morphology, it did not affect the markers or alter 11 the epithelial-like morphology of shMdm2 cells. TGFβ1 treatment of TMD231 cells did not cause 12
EMT as these cells are morphologically (spindle-shaped) and molecularly (no E-Cadherin, high snail, 13 vimentin, N-cadherin) mesenchymal-like (Fig. S1 ). Interestingly, despite having increased mutp53 14 levels, shMdm2 MDA468 cells did not have a mesenchymal phenotype, suggesting a mutant p53-15 independent role for Mdm2 in EMT. Taken together, these results indicate that Mdm2 plays an 16 important role in regulating key intracellular programing for EMT. 17
18
Migration and invasion are impaired in cells with decreased Mdm2 19 20
Since migration is coupled with EMT, we tested whether Mdm2 affected cellular migration. 21
Initially, we conducted traditional wound healing assays and quantified gap closure (Fig. 2a) . Gap 22 closure was dramatically delayed in shMdm2 MDA468 cells (50% at 70h) compared to shControl cells 23 (completed at 40h). To confirm these data, we also conducted a slight variation of the wound healing 24 assay by examining the migration of fluorescent cells off of coverslips. A GFP-shMdm2 plated 25 coverslip and a mCherry shControl plated coverslip were transferred and fixed on a new plate. Cells 1 that migrated into the void between the coverslips were then counted. This latter technique allowed 2 us to compare shMdm2 cells and shControl cells under the same conditions. shControl cells were 3 more effective at migration than shMdm2 cells (Fig. 2b) . Lastly, using a Boyden Chamber assay we 4 demonstrated that shControl cells were able to invade through matrigel more effectively than shMdm2 5 cells (Fig. 2c) . Thus, using three independent methods, our results show that migration and invasion 6 are diminished with decreased Mdm2. Since cell growth and migration can be inter-related, and shMdm2 cells exhibit a defect in 11 migration, we performed cell cycle analysis by Fluorescence-Activated Cell Sorting (FACS). 12
Interestingly, while both cell lines have mutp53 (elevated in shMdm2 MDA468), there were no 13 differences in cell cycle distribution between shControl and shMdm2 (Table S1 ). These data 14 eliminate the role of Mdm2 in regulating gain of function mutp53 in cell cycle and migration. To 15 garner insight into the role of Mdm2 in in vivo tumor growth, we orthotopically injected shControl or 16 shMdm2 MDA468 or TMD231 into the mammary fat pad of 6 week old NSG female mice (n=7 for 17 each group). The average tumor volumes and weights of shMdm2 MDA468 tumors were lower than 18 shControl tumors (Fig. 3a and 3b left panels) , despite allowing them to develop for 30 days longer. 19
This result is notable because mutp53 is thought to enhance tumorigenicity, and its levels are higher 20 in the shMdm2 MDA468 cell line. There were no significant differences between the final TMD231 21 tumor volumes or weight at the time of euthanasia (Fig. 3a and 3b, right panels) . 22
23
Mdm2 promotes vascularization 24 25 1 examined in vitro levels of key factors associated with angiogenesis. We and others have shown that 2 Mdm2 can play a role in stabilizing Hypoxia Inducible Factor 1 (HIF1 ) and up-regulating VEGF (39-3 41). Mdm2 can also stabilize VEGF mRNA levels to promote angiogenesis (42). In accordance with 4 these published findings, there was a substantial decrease in the levels of HIF1 and VEGF in both 5 the cultured TMD231 and MDA468 lines grown under normoxia or hypoxia when Mdm2 was 6 knocked-down compared to the shControl (Fig. 4a) . Based on these in vitro results, primary tumors 7 were sectioned and the endothelial cells were stained with cluster of differentiation 31 (CD31). In the 8 presence of Mdm2, the percentage of newly formed, immature vessels in both MDA468 and TMD231 9 shControl tumors was significantly higher than shMdm2 tumors (Fig. 4b) . We next analyzed lysates 10 from MDA468 and TMD231 shMdm2 tumor sets to confirm the in vitro results. In agreement with the 11 levels seen in cell culture (Fig.4a) , Fig. 4c demonstrates diminished HIF1 and VEGF levels in 12 shMdm2 tumors compared to shControl tumors. Taken together, our in vitro and in vivo data are 13 congruent in showing that Mdm2 is integrated into the angiogenesis pathway. 14 While our data suggest Mdm2 is an important driver of angiogenesis, previous reports 15 implicate mutp53 is also important for this phenomenon (27 ,43-45) . Considering that our cells 16 maintain mutp53, we tested the importance of this protein in angiogenesis by implanting TMD231 17 cells that had been transduced with either shControl or shp53 plasmid (Fig. S2) . Surprisingly, shp53 18 tumors had a significantly higher percentage of immature vessels compared to shControl tumors (Fig.  19   4b) . Analysis of tumor extracts revealed that Mdm2 levels were slightly elevated in shp53 tumors (Fig.  20   S2) . Thus, Mdm2 promotes vascularization of the tumor via regulation of the HIF1α-VEGF axis and 21 possibly permits intravasation of tumor cells into the blood stream. 22
Abrogation of Mdm2 results in diminished Metastasis 24 25
Considering the delay in tumor growth in both TMD231 and MDA468 shMdm2 cells, we Tumor cells undergo intracellular reprograming to signal for cellular migration. To assess if 1 these changes were evident in our in vivo metastasis models we examined EMT markers from 2 shMdm2 MDA468 tumor extracts. The results support our in vitro findings of decreased levels of N-3
Cadherin and SNAI1, and increased levels of E-Cadherin compared to the shControl tumors (Fig. 5a) . 4
Two additional proteins that are associated with metastasis, Plasminogen Activator Inhibitor-1 (PAI-5 1), an important tumor angiogenic factor involved in metastasis (46), and Matrix Metalloproteinase-2 6 (MMP2), a protein that acts to break down extracellular matrix and is associated with metastatic lung 7 foci (47) were examined by western blot analysis of tumor extracts. Both PAI-1 and MMP2 were 8 found to be decreased in shMdm2 primary tumors (Fig. 5a) . 9
These data indicate that the tumors cells are primed to intravaste and, with our angiogenesis 10 data in Figure 4 , suggest that shControl tumor cells would enter into the blood stream. We extracted 11 blood from the euthanized animals harboring shControl and shMdm2 tumors, and stained for human 12 EGFR to detect circulating tumor cells (CTC) by FACS analysis. We found a greater than four-fold 13 increase in CTC in animals implanted with MDA468 shControl cells compared to those implanted with 14 the shMdm2 cells (Fig. 5b) . Conversely, a greater number of shp53 CTC versus shControl CTC was 15
observed. This result is in accordance with the vasculature data shown in Figure 4 , but contradicts 16 published findings that suggest mutant p53 is driving metastasis (20) (21) (22) (23) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (48) (49) (50) . Thus, in the 17 presence of Mdm2, tumor cells are priming the vasculature and entering the blood stream. 18
After establishing that the numbers of tumor cells entering the blood stream was dependent on 19 Mdm2, we determined if a corresponding change in lung metastatic foci was evident. MDA468 20 shControl cells readily metastasized to the lung with an average of 1 foci/mm 2 , while the shMdm2 21 cells averaged only 0.15 foci in the same area. When Mdm2 was silenced, an 85% decrease in lung 22 foci was observed even with elevated mutp53 (Fig. 5c top) . Similarly, the TMD231 shControl cells 23
were significantly more likely to metastasize to the lung than shMdm2 cells (Fig. 5c middle) . 24 Surprisingly, considering the higher number of CTC in shp53 TMD231 cells, there were less 25 metastatic foci in the lungs compared to control animals (P=0.0046) (Fig. 5c bottom) . These results 1 are supported by the majority of publications implicating a role for mutp53 in metastasis (20-23,25-2 37,48-50) ; however, mutp53 is dispensible for metastatic initiation which requires Mdm2. 3 4
Discussion: 5 6
Here, we demonstrate that Mdm2 is extremely important in breast cancer metastases to the 7 lung. Specifically, we show that Mdm2 is important to promote cancer invasiveness via cell migration, 8 angiogenesis, and intravasation (Fig. 6) . Molecularly, Mdm2 stabilizes HIF1 which increases VEGF 9 and transcription factors associated with intracellular metastatic programming (such as SNAI1) (11). 10 This intracellular pathway increases angiogenesis, and the decrease of vasculature observed with 11 decreased Mdm2 provides one possible explanation for the small tumor size in the MDA468 shMdm2 12 tumors as well as the delay in tumor growth of TMD231 shMdm2 tumors. Therefore, the abundance 13 of CTC, and lung metastatic foci is reliant on the presence of Mdm2. Several studies have reported a 14 role for Mdm2 in migration or EMT in vitro. In contrast, our experiments were conducted in vivo, which 15 is significant in light of recent publications delineating the importance of the microenvironment in 16 tumor growth and invasion. 17
In addition to being essential in early metastasis, Mdm2 may also be important in later stages 18 as well. While extravasation and colonization was not directly assessed, at least one study has shown 19 that tail vein injection (bypassing the initial stages of metastasis) of transiently overexpressing Mdm2 20 in murine cells results in increased metastatic potential. This suggests that Mdm2 may have a role in 21 extravasion and/or foci formation. Not surprisingly, this study also demonstrated increased metastatic 22 potential with tail vein injected murine cells that were transiently knocked down for p53. The main 23 difference between this study and our study is that we knocked down gain-of-function p53 and not 24 wild type p53. The only other in vivo study that demonstrated a role for Mdm2 in metastasis was also 25 assay showing that MDA468 shControl cells (left) were able to close the gap in less time compared to 23 shMdm2 cells (right). Note: 0 h time points were imaged at 5X; all following time points were imaged 24 Hyp = 1% oxygen. Error bars represent ± SEM (n=7). Significances of differences were determined 1 using unpaired, 2-tailed, student's t tests (*P<0.05; **P<0.01; ***P<0.001). 2 analysis using human-specific EGFR revealed that there was less shMdm2 and more shp53 CTC 6 compared to the respective controls. (c) H&E stained lung sections (left) demonstrating decreased 7 metastasis with the shMdm2 implanted mice compared to those implanted with shControl cells. Only 8 the foci composed of greater than 25 cells were counted for the TMD231 shControl and shp53 9 implanted animals. All panels: shControl = shC; shMdm2= sh2. Error bars represent ± SEM (n=7). 10 Significances of differences were determined using unpaired, 2-tailed, student's t tests (ns= not 11 significant; *P<0.05; **P<0.01; ***P<0.001). 12 
